Literature DB >> 184108

Comparative activity of immunofluorescent antibody and complement-fixing antibody in cytomegalovirus infection.

R F Betts, S D George, R B Rundell, R B Freeman, R G Douglas.   

Abstract

Three different tests for detection of antibodies to human cytomegalovirus (CMV), complement fixing with antigen prepared by freeze-thaw disruption (CF-FT) or with antigen prepared by extraction with alkaline glycine buffer (CF-GE) and immunofluorescent staining (FA), were compared in renal transplant recipients and their healthy donors, FA and CF-GE tests yielded positive results at an identical and significantly higher frequency than CF-FT in both donors and recipients. CF-GE and FA performed on donors and recipients predicted all virus shedding post-transplant, whereas CF-FT did not. In the individuals who developed primary infection concurrent with the transplanted kidney, FA developed earlier than other antibodies in about one-half and at the same time in the remainder. In addition, the FA test could be completed more quickly and all sera could be interpreted, which made the FA test more useful than the CF-GE, but both of these tests were clearly superior to CF-FT.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184108      PMCID: PMC274416          DOI: 10.1128/jcm.4.2.151-156.1976

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Virologic and clinical observations on cytomegalic inclusion disease.

Authors:  T H WELLER; J B HANSHAW
Journal:  N Engl J Med       Date:  1962-06-14       Impact factor: 91.245

2.  Cervical cytomegalovirus excretion in pregnant and nonpregnant women: suppression in early gestation.

Authors:  S Stagno; D Reynolds; A Tsiantos; D A Fuccillo; R Smith; M Tiller; C A Alford
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

3.  Complement-fixing antibody in human sera reactive with viral and soluble antigens of cytomegalovirus.

Authors:  N E Cremer; N J Schmidt; F Jensen; M Hoffman; L S Oshiro; E H Lennette
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

4.  A study of complement-fixing, immunofluorescent, and neutralizing antibodies in human cytomegalovirus infections.

Authors:  U Krech; M Jung; W Sonnabend
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1971-06

5.  The use of an immunofluorescence technique for the determination of antibodies to cytomegalovirus strains in human sera.

Authors:  W T Chiang; B B Wentworth; E R Alexander
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

6.  Cytomegaloviremia following congenital infection.

Authors:  D J Lang; B Noren
Journal:  J Pediatr       Date:  1968-12       Impact factor: 4.406

7.  Cytomegalovirus complement-fixing antibody in microcephaly.

Authors:  J B Hanshaw
Journal:  N Engl J Med       Date:  1966-09-01       Impact factor: 91.245

8.  Demonstration of immunoglobulin G receptors induced by human cytomegalovirus.

Authors:  T Furukawa; E Hornberger; S Sakuma; S A Plotkin
Journal:  J Clin Microbiol       Date:  1975-10       Impact factor: 5.948

9.  The transplanted kidney as a source of cytomegalovirus infection.

Authors:  M Ho; S Suwansirikul; J N Dowling; L A Youngblood; J A Armstrong
Journal:  N Engl J Med       Date:  1975-11-27       Impact factor: 91.245

10.  Candidate cytomegalovirus strain for human vaccination.

Authors:  S A Plotkin; T Furukawa; N Zygraich; C Huygelen
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

View more
  16 in total

1.  Comparison of enzyme-linked immunosorbent assay (ELISA) technique and complement-fixation test for estimation of cytomegalovirus IgG antibody.

Authors:  J C Booth; G Hannington; T A Aziz; H Stern
Journal:  J Clin Pathol       Date:  1979-02       Impact factor: 3.411

2.  A comparison of complement fixation, indirect immunofluorescence for viral late antigens, and anti-complement immunofluorescence tests for the detection of cytomegalovirus specific serum antibodies.

Authors:  P D Griffiths; K J Buie; R B Heath
Journal:  J Clin Pathol       Date:  1978-09       Impact factor: 3.411

3.  Analysis of antibody assay methods and classes of viral antibodies in serodiagnosis of cytomegalovirus infection.

Authors:  N E Cremer; M Hoffman; E H Lennette
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

4.  Indirect fluorescent-antibody test for human cytomegalovirus infection in the absence of interfering immunoglobulin G receptors.

Authors:  N S Swack; F J Michalski; A Baumgarten; G D Hsiung
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

5.  Evaluation of anti-complement immunofluorescence test in cytomegalovirus infection.

Authors:  N Rao; D T Waruszewski; J A Armstrong; R W Atchison; M Ho
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

6.  Cytomegalovirus antigenic heterogeneity can cause false-negative results in indirect hemagglutination and complement fixation antibody assays.

Authors:  R G Faix
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

7.  Cellular immune response to cytomegalovirus infection after renal transplantation.

Authors:  C C Linnemann; C A Kauffman; M R First; G M Schiff; J P Phair
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

8.  Anticomplement immunofluorescence test that uses isolated fibroblast nuclei for detection of antibodies to human cytomegalovirus.

Authors:  L Mintz; R C Miner; A S Yeager
Journal:  J Clin Microbiol       Date:  1980-10       Impact factor: 5.948

9.  Application of a human osteogenic sarcoma cell culture for detection of human cytomegalovirus antibody by immunofluorescence tests.

Authors:  T Furukawa; R Herold; P Zolnick; S A Plotkin
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

10.  Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera.

Authors:  L Pereira; M Hoffman; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.